
{{header
| author     = | override_author = United States Congress
| translator = 
| section    = 
| previous   = 
| next       = 
| year       = 
| notes      = ''{{USBill|113|sres|97}}''
| categories =
| portal     =
| congress       = 113
| session        = 1
| title          = Expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs. ( sres97 ; 113th Congress)

| year           = 2013
| month          = 04
| day            = 15
| bill           = 97
| billtype       = sres
| purpose        = Expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.
}}
113 SRES 97 IS: Expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.U.S. Senate2013-04-15text/xmlENPursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
{{Center|113th CONGRESS}}


{{Center|1st Session}}


{{Center|S. RES. 97}}


{{Center|IN THE SENATE OF THE UNITED STATES}}


{{Center|April 15, 2013}}


{{Center|
[[w:|Mr. Coburn]] (for himself,
[[w:|Mr. Schumer]] , and
[[w:|Mr. McConnell]] ) submitted the following resolution; which was referred to the [[w:United States Senate Committee on Health, Education, Labor, and Pensions|Committee on Health, Education, Labor, and Pensions]] }}


{{Center|RESOLUTION}}

Expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.Whereas when abuse-deterrent formulations of a drug have been developed, approved, and recognized as effective by the [[w:Food and Drug Administration|Food and Drug Administration,]] the approval and marketing of generic versions that do not have abuse-deterrent features are likely to prevent achievement of the public health purposes of the efforts to develop such abuse-deterrent formulations;Whereas the [[w:Office of National Drug Control Policy|Office of National Drug Control Policy]] and the [[w:Food and Drug Administration|Food and Drug Administration]] have for many years strongly encouraged manufacturers of opioid drug products to develop abuse-deterrent formulations designed to prevent or discourage the abuse or misuse of those products;Whereas in response, several opioid drug manufacturers have developed abuse-deterrent formulations;Whereas efforts to reduce the level of abuse of opioid drug products are dependent on the widespread adoption of new technologies and approaches to the safer formulation of these drugs; andWhereas the [[w:Food and Drug Administration|Commissioner of Food and Drugs]] has acknowledged that the [[w:Food and Drug Administration|Food and Drug Administration]] has the authority under current law to require generic versions of products that have been formulated or reformulated with abuse-deterrent features to have comparable features: Now, therefore, be it

={{anchor|S1}} =

That it is the sense of the [[w:United States Senate|Senate]] that the [[w:Food and Drug Administration|Food and Drug Administration]] should exercise its acknowledged authority toâ€”
:(1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations recognized by the [[w:Food and Drug Administration|Food and Drug Administration]] as effective; and
:(2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.